Previous 10 | Next 10 |
home / stock / bvnkf / bvnkf news
Accelerated assessment allows for a shorter review period with EMA. Bavarian Nordic is on track to submit its Marketing Authorisation Application for CHIKV VLP to EMA during H1 2024. COPENHAGEN, Denmark, February 23, 2024 – Bavarian Nordic A/S (OMX: BAVA) (“the Company...
2024-02-21 15:09:19 ET More on Bavarian Nordic A/S Historical earnings data for Bavarian Nordic A/S Financial information for Bavarian Nordic A/S Read the full article on Seeking Alpha For further details see: Bavarian Nordic pulls plug on cancer vaccine ...
2023-11-16 13:13:08 ET Bavarian Nordic A/S (BVNKF) Q3 2023 Earnings Call Transcript November 16, 2023 08:00 AM ET Company Participants Rolf Sass Sorensen - Vice President of Investor Relations Paul Chaplin - President and Chief Executive Officer Henrik Juuel - Ex...
2023-09-01 12:45:33 ET More on Bavarian Nordic Bavarian Nordic A/S ( OTCPK:BVNKF ) Q2 2023 Earnings Call Transcript Bavarian Nordic receives $120m contract for manufacturing of smallpox and mpox vaccine from U.S. government Bavarian Nordic monkeypox vaccine Jynne...
2023-08-23 13:42:08 ET Bavarian Nordic A/S (BVNKF) Q2 2023 Earnings Conference Call August 23, 2023 8:00 AM ET Company Participants Rolf Sass Sorensen - Vice President Investor Relations Paul Chaplin - President and Chief Executive Officer Jean-Christophe May - E...
2023-08-23 12:03:27 ET Bavarian Nordic A/S press release ( OTCPK:BVNKF ): 1H net gain of DKK 914 million Revenue increased by 278% Y/Y to DKK 3,239 million. For further details see: Bavarian Nordic A/S reports 1H results
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority of subjects 22 days post a single vaccination. A fast and durable response was confirmed with high levels of immunity at both 2 weeks and 6 months post a ...
Contract award will support manufacturing of new bulk vaccine to partly replenish the inventory used for the mpox outbreak in 2022 Aims to strengthen the long-term U.S. stockpiling of smallpox vaccines Company upgrades its financial guidance for 2023 COPENHAGEN, Denmark, August 3,...
Booster study successfully met its primary objective, demonstrating non-inferiority to mRNA-vaccine Regulatory pathway will depend upon the outcome of secondary endpoints, reporting in the third quarter of 2023 COPENHAGEN, Denmark, June 27, 2023 – Bavarian Nordic A/S (OMX: BA...
Study successfully met its primary endpoints Data from second pivotal Phase 3 study in people aged 12 to 64 years expected in the third quarter 2023 COPENHAGEN, Denmark, June 20, 2023 – Bavarian Nordic A/S (OMX: BAVA) announced today the initial safety and immunogenicity resu...
News, Short Squeeze, Breakout and More Instantly...
Bavarian Nordic R/I Ord Company Name:
BVNKF Stock Symbol:
OTCMKTS Market:
Regulatory review of the single-dose CHIKV VLP vaccine candidate for immunization to prevent disease caused by chikungunya virus infection in individuals 12 years of age and older is now underway in both the EU and in the U.S. COPENHAGEN, Denmark, June 26, 2024 – Bavarian Nordic ...
First regulatory submission completed for CHIKV VLP seeking approval of the vaccine candidate for immunization against chikungunya virus infection in individuals 12 years of age and older Represents first BLA for a chikungunya vaccine for adolescents COPENHAGEN, Denmark, June 17, 2024...
COPENHAGEN, Denmark, April 29, 2024 – Bavarian Nordic A/S (OMX: BAVA) today announced that it has initiated the rolling submission process with the U.S. Food and Drug Administration (FDA) for a Biologics License Application (BLA) for the licensure of its CHIKV VLP vaccine candidate for i...